GENE ONLINE|News &
Opinion
Blog

2021-07-04| M&ASpecial

EQT Private Equity and Goldman Sachs Spend $8.5 Billion to Acquire Parexel

by Daniel Ojeda
Share To
On July 2nd, EQT Private Equity, a Swedish firm part of EQT AB, announced it would team up with Goldman Sachs to acquire Parexel, a clinical research organization (CRO). They would buy it from its current owner Pamplona Capital Management for $8.5 billion. The announcement comes amid EQT Private Equity’s restructuring of its healthcare-related holdings.  

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
READ MORE
EVENT
2023-03-28
Reuters Events: Pharma USA 2023
Philadelphia, USA
2023-04-24
Cell & Gene Therapy Summit 2023
Brussels, Belgium
2023-04-28
Boston Chinese Investment Club 2023 Biotech Pitch Competition
Boston, USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top